Lipocine Inc.
LPCN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001535955
No open-market purchases or sales by Lipocine Inc. insiders were filed in the last 90 days; 36 institutions reported holding it in 13F filings for Q2 2026, worth $7.63M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Lipocine Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 38 | 39 | +1 |
| Shares | 9.19M | 10.6M | +1.43M (+15.6%) |
| Value | $10.0M | $10.5M | +$506.9K (+5.1%) |
New holders (8)
Institutions that held Lipocine Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Wealth Effects LLC | 1,489,434 | $1.48M | 0.61% |
| Two Sigma Investments, LP | 102,600 | $102.0K | 0.00% |
| Two Sigma Advisers, LP | 53,000 | $53.0K | 0.00% |
| Charles Schwab Investment Management Inc | 50,000 | $50.0K | 0.00% |
| HRT Financial LP | 24,180 | $23.0K | 0.00% |
| Plante Moran Financial Advisors, LLC | 17,000 | $17.0K | 0.00% |
| Pinnacle Private Wealth, LLC | 15,250 | $15.0K | 0.00% |
| Goldman Sachs Group Inc | 14,187 | $14.0K | 0.00% |
Sold out (7)
Institutions that held Lipocine Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| XTX Topco Ltd | 28,762 | $31.0K |
| Barclays PLC | 24,075 | $26.0K |
| Qube Research & Technologies Ltd | 24,075 | $26.0K |
| Principal Financial Group Inc | 17,539 | $19.0K |
| Sutton Wealth Advisors Inc. | 1,000 | $1.09K |
| Global Wealth Management Investment Advisory, Inc. | 500 | $1.00K |
| Prentice Wealth Management LLC | 250 | – |